Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,773 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,496 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,526)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07743333 | Nebulized Lidocaine And Ketamine Before Fiberoptic Bronchoscopy | completed | Phase 4 | 134 | Alexandria UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05110196 | Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | completed | Phase 4 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).(GPS) |
| completed |
| Phase 4 |
| 182 |
| AstraZenecaINDUSTRY |
| 1 |
| Sep 11, 2025 |
| clinicaltrials |
| NCT03715205 | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | completed | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03285763 | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)(TAIL) | completed | Phase 4 | 619 | Hoffmann-La RocheINDUSTRY | 24 | Jan 23, 2025 | clinicaltrials |
| NCT04541706 | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | completed | Phase 4 | 100 | PfizerINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03656549 | Dose Individualization of Pemetrexed - IMPROVE-I(IMPROVE-I) | completed | Phase 4 | 6 | Radboud University Medical CenterOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03134456 | Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX | completed | Phase 4 | 50 | Samsung Medical CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04416633 | Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC | completed | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT03712969 | Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC | completed | Phase 4 | 527 | West China HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04511533 | Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | completed | Phase 4 | 101 | PfizerINDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT04180176 | Prospective Clinicogenomic Program(PCG) | completed | Phase 4 | 945 | Genentech, Inc.INDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05071703 | Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study | completed | Phase 4 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02869789 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | completed | Phase 4 | 1,041 | Bristol-Myers SquibbINDUSTRY | 21 | Jun 15, 2023 | clinicaltrials |
| NCT04074460 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study(VAPOR-C) | completed | Phase 4 | 169 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT03655834 | Dose Individualization of Pemetrexed - IMPROVE-III(IMPROVE-III) | completed | Phase 4 | 10 | Radboud University Medical CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT02275702 | Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients(APV) | completed | Phase 4 | 100 | Laval UniversityOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT03853551 | Osimertinib Study in Indian Patients | completed | Phase 4 | 60 | AstraZenecaINDUSTRY | 1 | Jun 3, 2021 | clinicaltrials |
| NCT03607149 | Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies(PKAPIR) | completed | Phase 4 | 11 | Centre Georges Francois LeclercOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT03444766 | Study of Nivolumab for Advanced Cancers in India | completed | Phase 4 | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT02514174 | Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older | completed | Phase 4 | 25 | Boehringer IngelheimINDUSTRY | 1 | Mar 30, 2020 | clinicaltrials |
| NCT03570645 | Comparison of the Duration of Ropivacaine Combined With Dexmedetomidine or Dexamethasone on Paravertebral Block | completed | Phase 4 | 154 | China Medical University, ChinaOTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT04145570 | A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions | completed | Phase 4 | 24 | Quadras Scientific SolutionsOTHER | 0 | Oct 30, 2019 | clinicaltrials |
| NCT03550482 | Oncoxin® and Quality of Life in Cancer Patients | completed | Phase 4 | 133 | Catalysis SLINDUSTRY | 2 | Jun 5, 2019 | clinicaltrials |
| NCT03092986 | Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer | completed | Phase 4 | 60 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Mar 8, 2019 | clinicaltrials |
| NCT02208843 | Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation | completed | Phase 4 | 60 | Boehringer IngelheimINDUSTRY | 7 | Dec 17, 2018 | clinicaltrials |
| NCT02151149 | Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly(ABOUND 70+) | completed | Phase 4 | 143 | CelgeneINDUSTRY | 1 | Sep 24, 2018 | clinicaltrials |
| NCT03384511 | The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. | completed | Phase 4 | 38 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT03394222 | Effect of Preoperative Budesonide Inhalation on Arterial Blood Oxygenation and Intrapulmonary Shunt During OLV | completed | Phase 4 | 50 | Fujian Medical University Union HospitalOTHER | 0 | Jan 9, 2018 | clinicaltrials |
| NCT00666978 | Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking | completed | Phase 4 | 540 | Lisa Sanderson Cox, PhDOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT00949910 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 4 | 6,586 | Hoffmann-La RocheINDUSTRY | 51 | Oct 5, 2016 | clinicaltrials |
| NCT02316327 | Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab | completed | Phase 4 | 19 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT01066884 | A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 4 | 5 | Hoffmann-La RocheINDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT00451906 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. | completed | Phase 4 | 2,252 | Hoffmann-La RocheINDUSTRY | 40 | May 24, 2016 | clinicaltrials |
| NCT02246023 | Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy | completed | Phase 4 | 78 | Daniel FranzenOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT00365508 | Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking | completed | Phase 4 | 642 | Fox Chase Cancer CenterOTHER | 1 | Mar 29, 2016 | clinicaltrials |
| NCT00770588 | Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)(INFORM) | completed | Phase 4 | 296 | AstraZenecaINDUSTRY | 1 | Feb 8, 2016 | clinicaltrials |
| NCT01402089 | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | completed | Phase 4 | 54 | Markus JoergerOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT01609543 | A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations | completed | Phase 4 | 62 | Hoffmann-La RocheINDUSTRY | 3 | Feb 1, 2016 | clinicaltrials |
| NCT02000531 | Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population | completed | Phase 4 | 45 | Hoffmann-La RocheINDUSTRY | 1 | Jan 13, 2016 | clinicaltrials |
| NCT01196078 | A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 4 | 114 | Hoffmann-La RocheINDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
| NCT02497118 | Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC | completed | Phase 4 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 14, 2015 | clinicaltrials |
| NCT02490059 | Ultrathin Bronchoscopy for Solitary Pulmonary Nodules(Babyscope) | completed | Phase 4 | 40 | University of ZurichOTHER | 1 | Jul 3, 2015 | clinicaltrials |
| NCT01741506 | Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer(COPPVATS) | completed | Phase 4 | 116 | Thomas Decker ChristensenOTHER | 1 | Jun 23, 2015 | clinicaltrials |
| NCT01287754 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations | completed | Phase 4 | 24 | Hoffmann-La RocheINDUSTRY | 1 | Jun 2, 2015 | clinicaltrials |
| NCT01230710 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression | completed | Phase 4 | 51 | Hoffmann-La RocheINDUSTRY | 1 | Mar 30, 2015 | clinicaltrials |
| NCT01465243 | Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose | completed | Phase 4 | 32 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 17, 2014 | clinicaltrials |
| NCT00747773 | Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung(CSAir 1) | completed | Phase 4 | 21 | CSA Medical, Inc.INDUSTRY | 1 | Jan 9, 2014 | clinicaltrials |
| NCT00883675 | Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer | completed | Phase 4 | 133 | Michael MannNETWORK | 2 | Dec 18, 2013 | clinicaltrials |
| NCT00762346 | Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis | completed | Phase 4 | 156 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Aug 3, 2026source: clinicaltrials